01:16 PM EDT, 06/10/2025 (MT Newswires) -- Novo Nordisk ( NVO ) has launched a new late-stage clinical trial to evaluate how well its experimental obesity drug CagriSema helps patients lose weight and maintain weight loss over the long term.

The trial, listed on ClinicalTrials.gov on Monday, will span approximately three years and three months and includes two parts comprising a main study and an extension study. In the main phase, participants will receive either CagriSema or a placebo, with a two-to-one chance of being assigned the active drug.

Those who receive CagriSema in the first phase will continue treatment in the extension study, while those on placebo will switch to the drug, while doses in "the extension study" will be randomly assigned, and all participants will receive weekly injections, according to the drugmaker's entry.

CagriSema, a combination of Cagrilintide and semaglutide, is being tested by Novo Nordisk ( NVO ) as a next-generation successor to Wegovy, Reuters said.

Novo Nordisk ( NVO ) didn't immediately respond to a request for comment from MT Newswires.

Shares of Novo Nordisk ( NVO ) were up more than 6% in recent Tuesday trading.

Price: 80.16, Change: +4.69, Percent Change: +6.21